OBJECTIVES: To evaluate the impact of histological variants on oncological outcomes of patients with muscle-invasive bladder cancer treated with open radical cystectomy and furthermore to determine any association between survival and each histotype of bladder cancer. MATERIALS AND METHODS: Data from 525 consecutive patients with muscle-invasive bladder cancer treated with radical cystectomy between January 2008 and May 2019 were collected retrospectively. The Kaplan-Meier curves and multivariable analysis addressed the role of histological variants in recurrence, cancer-specific and overall mortality between all subgroups. RESULTS: Of 525 patients, 131 (25.0%) showed a histological variant at radical cystectomy. With a median follow-up of 31 months, 209 (39.8%) recurrences, 184 (35.0%) cancer-related deaths and 260 (49.5%) overall deaths were reported. The presence of histological variant was associated with advanced tumour stage, the presence of concomitant carcinoma in situ, lymph node metastasis, lymphovascular invasion and positive surgical margins compared to pure urothelial bladder cancer (all p values < .008) and resulted as an independent risk factor for cancer-specific mortality (p = 0.001). Patients with a histological variant were at significantly higher risk for recurrence, cancer-specific mortality and overall mortality (all p values ≤ .001). Micropapillary, sarcomatoid or small cell differentiation was associated with reduced survival. CONCLUSION: The presence of histological variants at radical cystectomy seems to be weakly associated with reduced survival compared to pure urothelial bladder cancer paired for pathologic stage. The association of histological variants with advanced and biologically aggressive tumours suggests the need for attention on the overall management of these patients, in particular for micropapillary, sarcomatoid and small cell differentiation.
OBJECTIVES: To evaluate the impact of histological variants on oncological outcomes of patients with muscle-invasive bladder cancer treated with open radical cystectomy and furthermore to determine any association between survival and each histotype of bladder cancer. MATERIALS AND METHODS: Data from 525 consecutive patients with muscle-invasive bladder cancer treated with radical cystectomy between January 2008 and May 2019 were collected retrospectively. The Kaplan-Meier curves and multivariable analysis addressed the role of histological variants in recurrence, cancer-specific and overall mortality between all subgroups. RESULTS: Of 525 patients, 131 (25.0%) showed a histological variant at radical cystectomy. With a median follow-up of 31 months, 209 (39.8%) recurrences, 184 (35.0%) cancer-related deaths and 260 (49.5%) overall deaths were reported. The presence of histological variant was associated with advanced tumour stage, the presence of concomitant carcinoma in situ, lymph node metastasis, lymphovascular invasion and positive surgical margins compared to pure urothelial bladder cancer (all p values < .008) and resulted as an independent risk factor for cancer-specific mortality (p = 0.001). Patients with a histological variant were at significantly higher risk for recurrence, cancer-specific mortality and overall mortality (all p values ≤ .001). Micropapillary, sarcomatoid or small cell differentiation was associated with reduced survival. CONCLUSION: The presence of histological variants at radical cystectomy seems to be weakly associated with reduced survival compared to pure urothelial bladder cancer paired for pathologic stage. The association of histological variants with advanced and biologically aggressive tumours suggests the need for attention on the overall management of these patients, in particular for micropapillary, sarcomatoid and small cell differentiation.
Authors: Giacomo Novara; Robert S Svatek; Pierre I Karakiewicz; Eila Skinner; Vincenzo Ficarra; Yves Fradet; Yair Lotan; Hendrik Isbarn; Umberto Capitanio; Patrick J Bastian; Wassim Kassouf; Hans-Martin Fritsche; Jonathan I Izawa; Derya Tilki; Colin P Dinney; Seth P Lerner; Mark Schoenberg; Bjoern G Volkmer; Arthur I Sagalowsky; Shahrokh F Shariat Journal: J Urol Date: 2010-06 Impact factor: 7.450
Authors: Gladell P Paner; Walter M Stadler; Donna E Hansel; Rodolfo Montironi; Daniel W Lin; Mahul B Amin Journal: Eur Urol Date: 2018-01-09 Impact factor: 20.096
Authors: Ryan P Dorin; Siamak Daneshmand; Manuel S Eisenberg; Shahin Chandrasoma; Jie Cai; Gus Miranda; Peter W Nichols; Donald G Skinner; Eila C Skinner Journal: Eur Urol Date: 2011-07-14 Impact factor: 20.096
Authors: Andrea Necchi; Daniele Raggi; Andrea Gallina; Russell Madison; Maurizio Colecchia; Roberta Lucianò; Rodolfo Montironi; Patrizia Giannatempo; Elena Farè; Filippo Pederzoli; Marco Bandini; Marco Bianchi; Renzo Colombo; Giorgio Gandaglia; Nicola Fossati; Laura Marandino; Umberto Capitanio; Federico Dehò; Siraj M Ali; Jon H Chung; Jeffrey S Ross; Andrea Salonia; Alberto Briganti; Francesco Montorsi Journal: Eur Urol Date: 2019-11-08 Impact factor: 20.096
Authors: Sarah Minkler; Fabrice Lucien; Michael J Kimber; Dipak K Sahoo; Agnes Bourgois-Mochel; Margaret Musser; Chad Johannes; Igor Frank; John Cheville; Karin Allenspach; Jonathan P Mochel Journal: Cancers (Basel) Date: 2021-01-23 Impact factor: 6.639
Authors: Giovanni La Croce; Richard Naspro; Marco Finati; Federico Pellucchi; Mario Sodano; Michele Manica; Michele Catellani; Andrea Gianatti; Marco Roscigno; Luigi Filippo Da Pozzo Journal: J Clin Med Date: 2022-01-22 Impact factor: 4.241